BACKGROUND: Neurofibrillary tangles (NFTs), composed of hyperphosphorylated tau proteins, are one of the pathologic hallmarks of Alzheimer disease (AD). We aimed to determine whether patterns of gray matter atrophy from antemortem MRI correlate with Braak staging of NFT pathology. METHODS: Eighty-three subjects with Braak stage III through VI, a pathologic diagnosis of low- to high-probability AD, and MRI within 4 years of death were identified. Voxel-based morphometry assessed gray matter atrophy in each Braak stage compared with 20 pathologic control subjects (Braak stages 0 through II). RESULTS: In pairwise comparisons with Braak stages 0 through II, a graded response was observed across Braak stages V and VI, with more severe and widespread loss identified at Braak stage VI. No regions of loss were identified in Braak stage III or IV compared with Braak stages 0 through II. The lack of findings in Braak stages III and IV could be because Braak stage is based on the presence of any NFT pathology regardless of severity. Actual NFT burden may vary by Braak stage. Therefore, tau burden was assessed in subjects with Braak stages 0 through IV. Those with high tau burden showed greater gray matter loss in medial and lateral temporal lobes than those with low tau burden. CONCLUSIONS: Patterns of gray matter loss are associated with neurofibrillary tangle (NFT) pathology, specifically with NFT burden at Braak stages III and IV and with Braak stage itself at higher stages. This validates three-dimensional patterns of atrophy on MRI as an approximate in vivo surrogate indicator of the full brain topographic representation of the neurodegenerative aspect of Alzheimer disease pathology.
BACKGROUND: Neurofibrillary tangles (NFTs), composed of hyperphosphorylated tau proteins, are one of the pathologic hallmarks of Alzheimer disease (AD). We aimed to determine whether patterns of gray matter atrophy from antemortem MRI correlate with Braak staging of NFT pathology. METHODS: Eighty-three subjects with Braak stage III through VI, a pathologic diagnosis of low- to high-probability AD, and MRI within 4 years of death were identified. Voxel-based morphometry assessed gray matter atrophy in each Braak stage compared with 20 pathologic control subjects (Braak stages 0 through II). RESULTS: In pairwise comparisons with Braak stages 0 through II, a graded response was observed across Braak stages V and VI, with more severe and widespread loss identified at Braak stage VI. No regions of loss were identified in Braak stage III or IV compared with Braak stages 0 through II. The lack of findings in Braak stages III and IV could be because Braak stage is based on the presence of any NFT pathology regardless of severity. Actual NFT burden may vary by Braak stage. Therefore, tau burden was assessed in subjects with Braak stages 0 through IV. Those with high tau burden showed greater gray matter loss in medial and lateral temporal lobes than those with low tau burden. CONCLUSIONS: Patterns of gray matter loss are associated with neurofibrillary tangle (NFT) pathology, specifically with NFT burden at Braak stages III and IV and with Braak stage itself at higher stages. This validates three-dimensional patterns of atrophy on MRI as an approximate in vivo surrogate indicator of the full brain topographic representation of the neurodegenerative aspect of Alzheimer disease pathology.
Authors: Matthew L Senjem; Jeffrey L Gunter; Maria M Shiung; Ronald C Petersen; Clifford R Jack Journal: Neuroimage Date: 2005-04-12 Impact factor: 6.556
Authors: Keith A Josephs; Jennifer L Whitwell; Joseph E Parisi; David S Knopman; Bradley F Boeve; Yonas E Geda; Clifford R Jack; Ronald C Petersen; Dennis W Dickson Journal: Neurobiol Aging Date: 2006-12-26 Impact factor: 4.673
Authors: G Chételat; B Landeau; F Eustache; F Mézenge; F Viader; V de la Sayette; B Desgranges; J-C Baron Journal: Neuroimage Date: 2005-10-01 Impact factor: 6.556
Authors: Jennifer L Whitwell; Stephen D Weigand; Maria M Shiung; Bradley F Boeve; Tanis J Ferman; Glenn E Smith; David S Knopman; Ronald C Petersen; Eduardo E Benarroch; Keith A Josephs; Clifford R Jack Journal: Brain Date: 2007-01-31 Impact factor: 13.501
Authors: Keith A Josephs; Jennifer L Whitwell; Zeshan Ahmed; Maria M Shiung; Stephen D Weigand; David S Knopman; Bradley F Boeve; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson; Clifford R Jack Journal: Ann Neurol Date: 2008-02 Impact factor: 10.422
Authors: Jennifer L Whitwell; Scott A Przybelski; Stephen D Weigand; David S Knopman; Bradley F Boeve; Ronald C Petersen; Clifford R Jack Journal: Brain Date: 2007-05-28 Impact factor: 13.501
Authors: Julie A Schneider; Patricia A Boyle; Zoe Arvanitakis; Julia L Bienias; David A Bennett Journal: Ann Neurol Date: 2007-07 Impact factor: 10.422
Authors: Madhav Thambisetty; Jing Wan; Aaron Carass; Yang An; Jerry L Prince; Susan M Resnick Journal: Neuroimage Date: 2010-05-02 Impact factor: 6.556
Authors: Prashanthi Vemuri; Gyorgy Simon; Kejal Kantarci; Jennifer L Whitwell; Matthew L Senjem; Scott A Przybelski; Jeffrey L Gunter; Keith A Josephs; David S Knopman; Bradley F Boeve; Tanis J Ferman; Dennis W Dickson; Joseph E Parisi; Ronald C Petersen; Clifford R Jack Journal: Neuroimage Date: 2010-12-31 Impact factor: 6.556
Authors: H Matsuda; S Mizumura; K Nemoto; F Yamashita; E Imabayashi; N Sato; T Asada Journal: AJNR Am J Neuroradiol Date: 2012-02-02 Impact factor: 3.825
Authors: E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel Journal: J Prev Alzheimers Dis Date: 2014-12
Authors: W J P Henneman; H Vrenken; J Barnes; I C Sluimer; N A Verwey; M A Blankenstein; M Klein; N C Fox; P Scheltens; F Barkhof; W M van der Flier Journal: Neurology Date: 2009-09-22 Impact factor: 9.910
Authors: Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski Journal: Lancet Neurol Date: 2010-01 Impact factor: 44.182